These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 17629586)

  • 1. Soluble CD163 from activated macrophages predicts mortality in acute liver failure.
    Møller HJ; Grønbaek H; Schiødt FV; Holland-Fischer P; Schilsky M; Munoz S; Hassanein T; Lee WM;
    J Hepatol; 2007 Nov; 47(5):671-6. PubMed ID: 17629586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage activation marker, soluble CD163, is an independent predictor of short-term mortality in patients with cirrhosis and bacterial infection.
    Tornai T; Vitalis Z; Sipeki N; Dinya T; Tornai D; Antal-Szalmas P; Karanyi Z; Tornai I; Papp M
    Liver Int; 2016 Nov; 36(11):1628-1638. PubMed ID: 27031405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus.
    Dultz G; Gerber L; Farnik H; Berger A; Vermehren J; Pleli T; Zeuzem S; Piiper A; Kronenberger B; Waidmann O
    J Viral Hepat; 2015 Apr; 22(4):427-32. PubMed ID: 25181653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis.
    Waidmann O; Brunner F; Herrmann E; Zeuzem S; Piiper A; Kronenberger B
    J Hepatol; 2013 May; 58(5):956-61. PubMed ID: 23333526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of soluble CD163 as a specific marker of macrophage/monocyte activity in sarcoidosis patients.
    Tanimura H; Mizuno K; Okamoto H
    Sarcoidosis Vasc Diffuse Lung Dis; 2015 Jul; 32(2):99-105. PubMed ID: 26278688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C.
    Kazankov K; Barrera F; Møller HJ; Bibby BM; Vilstrup H; George J; Grønbaek H
    Hepatology; 2014 Aug; 60(2):521-30. PubMed ID: 24623375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).
    Grønbæk H; Rødgaard-Hansen S; Aagaard NK; Arroyo V; Moestrup SK; Garcia E; Solà E; Domenicali M; Piano S; Vilstrup H; Møller HJ;
    J Hepatol; 2016 Apr; 64(4):813-22. PubMed ID: 26639396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
    Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
    Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis.
    Baeten D; Møller HJ; Delanghe J; Veys EM; Moestrup SK; De Keyser F
    Arthritis Rheum; 2004 May; 50(5):1611-23. PubMed ID: 15146432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD.
    Axelsson J; Møller HJ; Witasp A; Qureshi AR; Carrero JJ; Heimbürger O; Bárány P; Alvestrand A; Lindholm B; Moestrup SK; Stenvinkel P
    Am J Kidney Dis; 2006 Dec; 48(6):916-25. PubMed ID: 17162146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs.
    Greisen SR; Møller HJ; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Hvid M; Deleuran B
    Clin Exp Rheumatol; 2015; 33(4):498-502. PubMed ID: 25962601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma.
    Andersen MN; Abildgaard N; Maniecki MB; Møller HJ; Andersen NF
    Eur J Haematol; 2014 Jul; 93(1):41-7. PubMed ID: 24612259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis.
    Grønbaek H; Sandahl TD; Mortensen C; Vilstrup H; Møller HJ; Møller S
    Aliment Pharmacol Ther; 2012 Jul; 36(2):173-80. PubMed ID: 22591184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of serum sCD163 in patients with liver diseases and inflammatory disorders.
    Wang J; Yu Y; Yang Y; Wu SS; Zhu HH; Liu YN; Liu WX; Hu Y; Wu W; Xia CX; Chen Z
    Int J Clin Exp Pathol; 2015; 8(7):8419-25. PubMed ID: 26339412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
    Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum neopterin and soluble CD163 as markers of macrophage activation in paracetamol (acetaminophen)-induced human acute liver injury.
    Craig DG; Lee P; Pryde EA; Hayes PC; Simpson KJ
    Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1395-404. PubMed ID: 24138337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.
    Laursen TL; Wong GL; Kazankov K; Sandahl T; Møller HJ; Hamilton-Dutoit S; George J; Chan HL; Grønbaek H
    J Gastroenterol Hepatol; 2018 Feb; 33(2):484-491. PubMed ID: 28618015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163.
    Møller HJ; Moestrup SK; Weis N; Wejse C; Nielsen H; Pedersen SS; Attermann J; Nexø E; Kronborg G
    Crit Care Med; 2006 Oct; 34(10):2561-6. PubMed ID: 16915112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma.
    Kazankov K; Rode A; Simonsen K; Villadsen GE; Nicoll A; Møller HJ; Lim L; Angus P; Kronborg I; Arachchi N; Gorelik A; Liew D; Vilstrup H; Frystyk J; Grønbæk H
    Scand J Clin Lab Invest; 2016; 76(1):64-73. PubMed ID: 26549495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study.
    Andersen ES; Rødgaard-Hansen S; Moessner B; Christensen PB; Møller HJ; Weis N
    Eur J Clin Microbiol Infect Dis; 2014 Jan; 33(1):117-22. PubMed ID: 24424890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.